



LJMU Research Online

Paini, A, Leonard, JA, Joossens, E, Bessems, JGM, Desalegn, A, Dorne, JL, Gosling, JP, Heringa, MB, Klaric, M, Kliment, T, Kramer, NI, Loizou, G, Louise, J, Lumen, A, Madden, JC, Patterson, EA, Proença, S, Punt, A, Setzer, RW, Suciu, N, Troutman, J, Yoon, M, Worth, A and Tan, YM

Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making

<http://researchonline.ljmu.ac.uk/id/eprint/9770/>

Article

Citation (please note it is advisable to refer to the publisher's version if you intend to cite from this work)

Paini, A, Leonard, JA, Joossens, E, Bessems, JGM, Desalegn, A, Dorne, JL, Gosling, JP, Heringa, MB, Klaric, M, Kliment, T, Kramer, NI, Loizou, G, Louise, J, Lumen, A, Madden, JC, Patterson, EA, Proença, S, Punt, A, Setzer, RW, Suciu, N, Troutman, J, Yoon, M, Worth, A and Tan, YM (2018)

LJMU has developed **LJMU Research Online** for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain.

The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription.

For more information please contact researchonline@ljmu.ac.uk

<http://researchonline.ljmu.ac.uk/>

1 **Title:** Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision
2 making

3 **Authors:** Paini A^{1*}, Leonard JA², Joossens E¹, Bessems JGM^{1, 18}, Desalegn A¹, Dorne JL³, Gosling JP⁴,
4 Heringa MB⁵, Klaric M⁶, Kliment T¹, Kramer NI⁷, Loizou G⁸, Louisse J^{9, 13}, Lumen A¹⁰, Madden JC¹¹,
5 Patterson EA¹², Proença S^{1,7}, Punt A¹³, Setzer RW¹⁴, Suci N¹⁵, Troutman J¹⁶, Yoon M^{17, 19}, Worth A¹, Tan
6 YM¹⁴.

7 *Corresponding Author: Alicia.paini@ec.europa.eu

8 Affiliations

9 ¹ European Commission Joint Research Centre, Ispra, Italy.

10 ² Oak Ridge Institute for Science and Education, 100 ORAU Way, Oak Ridge, TN 37830, USA.

11 ³ European Food Safety Authority, 1a, Via Carlo Magno, 1A, 43126 Parma PR, Italy.

12 ⁴ School of Mathematics, University of Leeds, Leeds, U.K.

13 ⁵ RIVM - The National Institute for Public Health and the Environment, Bilthoven, The Netherlands.

14 ⁶ Cosmetics Europe, Brussels, Belgium

15 ⁷ Institute for Risk Assessment Sciences, Utrecht University, P.O. Box 80177, 3508TD Utrecht, The
16 Netherlands.

17 ⁸ Health and Safety Executive, Buxton, UK

18 ⁹ Division of Toxicology, Wageningen University, Tuinlaan 5, 6703 HE Wageningen, The Netherlands.

19 ¹⁰ Division of Biochemical Toxicology, National Center for Toxicological Research, US Food and Drug
20 Administration, Jefferson, AR 72079, USA.

21 ¹¹ School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Byrom Street,
22 Liverpool L3 3AF, UK.

23 ¹² School of Engineering, University of Liverpool, Liverpool, L69 3GH, UK.

24 ¹³RIKILT Wageningen University and Research, Akkermaalsbos 2, 6708 WB, Wageningen, The
25 Netherlands.

26 ¹⁴ U.S. Environmental Protection Agency, National Exposure Research Laboratory, 109 TW Alexander
27 Drive, Research Triangle Park, NC 27709, USA

28 ¹⁵ DiSTAS, Università Cattolica del Sacro Cuore, Piacenza, Italy.

29 ¹⁶ Central Product Safety, The Procter & Gamble Company, Cincinnati, OH, USA.

30 ¹⁷ ScitoVation, 6 Davis Drive, PO Box 110566, Research Triangle Park, NC 27709, USA

31 ¹⁸ Flemish Institute for Technological Research (VITO), Mol, Belgium

32 ¹⁹ ToxStrategies, Research Triangle Park Office, 1249 Kildaire Farm Road 134, Cary, NC 27511, USA

33

34 **Highlights**

35 PBK models have helped to facilitate quantitative *in vitro* to *in vivo* extrapolation

36 PBK modelling has the potential to play a significant role in reducing animal testing

37 It is critical to assess the validity of PBK models built using non-animal data

38 A framework is needed for communicating characteristics and results of PBK modelling

39

40

41

42

43 **Abstract**

44 The fields of toxicology and chemical risk assessment seek to reduce, and eventually replace, the use of animals
45 for the prediction of toxicity in humans. In this context, physiologically based kinetic (PBK) modelling based on
46 *in vitro* and *in silico* kinetic data has the potential to play a significant role in reducing animal testing, by providing
47 a methodology capable of incorporating *in vitro* human data to facilitate the development of *in vitro* to *in vivo*
48 extrapolation of hazard information. In the present article, we discuss the challenges in: 1) applying PBK
49 modelling to support regulatory decision making under the toxicology and risk-assessment paradigm shift
50 towards animal replacement; 2) constructing PBK models without *in vivo* animal kinetic data, while relying solely
51 on *in vitro* or *in silico* methods for model parameterization; and 3) assessing the validity and credibility of PBK
52 models built largely using non-animal data. The strengths, uncertainties, and limitations of PBK models
53 developed using *in vitro* or *in silico* data are discussed in an effort to establish a higher degree of confidence in
54 the application of such models in a regulatory context. The article summarises the outcome of an expert
55 workshop hosted by the European Commission Joint Research Centre (EC-JRC) - European Union Reference
56 Laboratory for Alternatives to Animal Testing (EURL ECVAM), on “Physiologically-Based Kinetic modelling in risk
57 assessment – reaching a whole new level in regulatory decision-making” held in Ispra, Italy, in November 2016,
58 along with results from an international survey conducted in 2017 and recently reported activities occurring
59 within the PBK modelling field. The discussions presented herein highlight the potential applications of next
60 generation (NG)-PBK modelling, based on new data streams.

61 **Keywords:** Physiologically Based kinetic models; PBPK; PBTK; Toxicokinetics; *In vitro*; *In silico*.-

62 Introduction

63 Modelling and simulation based approaches are gradually gaining interest as critical tools for safety and risk
64 assessment of a variety of compounds including drugs, chemicals, consumer products, and food ingredients.
65 These modelling approaches are recognised for the crucial role they play in, for example, predicting the
66 biokinetics of drugs and chemicals in the organism without the need to conduct *in vivo* experiments. For more
67 than 40 years, physiologically-based kinetic (PBK) models have been used to simulate biokinetics (Andersen and
68 Krishnan, 2010; Mumtaz et al., 2012; Krishnan and Peyret, 2009; Bois et al., 2017). In PBK models, the body is
69 represented as a series of interconnected compartments linked via blood flow, as depicted in the schematic
70 below (Figure 1a), to simulate concentration-time curves in target organs or their surrogates, such as in blood
71 (Figure 1b). PBK models use differential equations to describe the absorption, distribution, metabolism, and
72 elimination (ADME) processes that govern the fate and transport of the chemical among these interconnected
73 compartments. Proper use of PBK models helps to reduce uncertainties and to identify data gaps inherent in
74 hazard characterisation approaches that rely upon default extrapolation factors (e.g., a multiplication factor of
75 10 for inter-species extrapolation) to derive health-based guidance values from animal toxicity studies. PBK
76 models provide a sound scientific basis to extrapolate across species, routes of exposure, and exposure
77 scenarios, based on physiology and (physico-)chemical properties (Loizou et al., 2008; Bessems et al., 2014). As
78 PBK models can be developed for specific individuals within the human population, they provide a means for
79 quantifying inter-individual differences in kinetics, allowing for the determination of extrapolation factors across
80 age groups or across populations of varying susceptibilities. With this information, safe chemical intake levels
81 can be derived for individuals and populations. Most recently, PBK models have helped to facilitate quantitative
82 *in vitro* to *in vivo* extrapolation (QIVIVE) approaches (Yoon et al., 2012, 2014, 2015; Wetmore et al., 2015; Louise
83 et al., 2017), enabling the use of *in vitro* toxicity data for the setting of safe intake levels. QIVIVE is an essential
84 process in linking an *in vitro* measured biological (adverse) readout to a potential *in vivo* outcome (Groothuis et
85 al., 2015). QIVIVE provides a means of considering exposure and dosimetry, and enables the use of *in vitro*
86 toxicity data for risk-based assessments beyond hazard-based assessments (Bell et al., 2018). Once an *in vitro*
87 concentration-response has been generated, the benchmark dose approach can be applied to the predicted
88 dose – response data, to obtain an *in vitro*-based point of departure (PoD) or Reference Point (RfP) (Louisse et
89 al., 2015; 2017).

90 Nomenclature

91 “Physiologically based pharmacokinetic” (PBPK) model is the most widely used term and was developed by the
92 pharmaceutical field to simulate the kinetics of drugs. Despite the popular use of the term, “PBPK” is not entirely
93 correct in the context of general chemical risk assessment. Another term preferred in the European Union (EU)
94 and related to chemical risk assessment is “PBTk”, where TK is the abbreviation for “toxicokinetics”. However,
95 this term is not entirely appropriate either (Clewell et al., 2008). Rather, a more general nomenclature, such as
96 physiologically based biokinetic (PBBK) or the aforementioned PBK, might be seen as more appropriate.
97 Regardless of the terminology used, PBK, PBPK, PBBK and PBTk can all be considered synonyms, and so

98 throughout this document we will consistently use the more general terms of PBK model or PBK modelling. It is
99 noted that the ever-increasing advancements *in vitro* and *in silico* methodologies in the field of toxicology can
100 be used in combination with PBK models to support regulatory decisions on the use of chemical substances. In
101 the present manuscript the term next generation PBK (NG-PBK) model will be used to name these models. This
102 term, NG-PBK, refers to PBK models that are developed without the provision of newly produced (i.e., without
103 animal sacrifice) animal TK data for parametrisation and validation of those models, but rather through
104 supporting *in vitro*, *in silico*, -omics, micro-scale applications. NG-PBK models representing the human body
105 should be parameterized and validated using *in vitro*, *in silico*, -omics data, micro-scale systems, and human *in*
106 *vivo* data, when available. This stands also for PBK models built to represent animals (e.g. livestock, fish, bees),
107 which should be parameterized and validated using *in vitro*, *in silico*, -omics, micro-scale systems and historical
108 or (bio)-monitoring animal data of the species of interest, to avoid the need for animal sacrifice.

109 **Milestones in the history of PBK modelling**

110 The principles behind PBK modelling were first reported in 1937 by Teorell, in a publication entitled “Kinetics of
111 distribution of substances administered to the body” (Teorell, 1937). Although Teorell’s work was the first
112 attempt to describe the body as a series of equations, the complexity of the mathematics, lack of data, and lack
113 of computing power rendered his concepts incomplete until the 1960s. Between the 1960s and 1970s, several
114 PBK models were developed for pharmaceutical drugs to target cancers (Bischoff and Dedrick 1968; Bischoff et
115 al. 1970). These publications paved the way for more than 2000 articles written on the topic of PB(P/T)K
116 modelling within the last forty years (Figure 2a). Over the past decade, there has been an increase in the
117 development of PBK models for use in a variety of scientific fields, such as pharmacology, forensic sciences, and
118 chemical risk assessment (Figure 2b), although such an increase was not seen for toxicology and veterinary
119 medicine. Many risk assessors remain reluctant to apply these models within their work (Paini et al. 2017b, Punt
120 et al., 2017, 2018), as PBK models are not often included in current hazard characterization and risk assessment
121 protocols. In addition, some regulatory agencies may often have limited experience in using PBK models, and
122 the complexity associated with the evaluation of model performance has also contributed to this reluctance.

123 Over the past 20 years, several workshops have been held to promote the applicability of PBK models in the
124 academic, industrial, and regulatory sectors. For example, a 1995 European Centre for the Validation of
125 Alternative Methods (ECVAM) workshop discussing the use of biokinetic and *in vitro* methods resulted in 15
126 recommendations that were submitted to support and guide future work in the PBK modelling field (Blaauboer
127 et al., 1996). This workshop was followed by many others to better define the potential role of PBK modelling in
128 science and risk assessment following a Three R (replacement, reduction and refinement) strategy (Bouvier
129 d’Yvoire et al., 2007). In the same year, a workshop to address uncertainty and variability analysis in PBK
130 modeling was held by Barton et al. (2007). Loizou et al. (2008) reported the need for clear descriptions of good
131 modelling practices (GMP) for: 1) model development; 2) model characterisation; 3) model documentation; and
132 4) model evaluation. A subsequent thematic workshop aimed to critically appraise PBK modelling software
133 platforms and to provide a more detailed state-of-the-art overview of non-animal based PBK parameterisation
134 tools (Bessemers et al., 2014). A CEN (European Committee for Standardization) workshop in 2014 strived for

135 agreement upon the minimum requirements for the amount and type of information to be provided for
136 exposure models, such as PBK models, along with documentation and guidelines for the structure and reporting
137 of such information. The resulting CEN workshop agreement (CWA) was expected to provide a more rigorous
138 means of describing exposure models and to aid users in better understanding them (Ciffroy et al., 2016a;
139 Altenphol et al., 2018). The following year, a workshop assessed the state of knowledge in the application of PBK
140 models in regulatory decision-making, in addition to sharing and discussing best practices in the use of PBK
141 modelling to inform dose selection in specific patient populations (Wagner et al., 2015). In 2017, a workshop
142 organized by the National Centre for the Replacement, Refinement, and Reduction of Animals in Research
143 (NC3Rs) encouraged experts in exposure science to consider the role of PBK models in the extrapolation of
144 external exposure data to internal concentrations to promote the application of non-animal data in efficacy and
145 safety testing (Burden et al., 2017; [https://www.nc3rs.org.uk/applying-exposure-science-increase-utility-non-](https://www.nc3rs.org.uk/applying-exposure-science-increase-utility-non-animal-data-efficacy-and-safety-testing)
146 [animal-data-efficacy-and-safety-testing](https://www.nc3rs.org.uk/applying-exposure-science-increase-utility-non-animal-data-efficacy-and-safety-testing)). A Lorentz Center workshop entitled “Non-animal Methods for
147 Toxicokinetics: Meeting New Paradigms in Toxicology” was held at the end of 2017 and emphasized the role of
148 PBK models (<https://www.lorentzcenter.nl/lc/web/2017/943/info.php3?wsid=943&venue=Oort;>
149 <https://www.lorentzcenter.nl/lc/web/2017/943/report.pdf>). The first European Partnership for Alternative
150 Approaches to Animal Testing (EPAA) partners’ forum, held at the end of 2017, aimed to provide an overview
151 on toxicokinetics and read-across with insight into the role of PBK models (Laroche et al., 2018).

152

153 **Framing the problem**

154 The EURL ECVAM Strategy on Toxicokinetics¹, as published in 2015, outlines opportunities for generating and
155 making better use of TK data. The central feature of the strategy focuses on the use of PBK modelling to integrate
156 data from *in vitro* and *in silico* methods for prediction of human whole-body biokinetic behavior, and enables
157 QIVIVE to obtain safety guidance values expressed as external doses (Bell et al., 2018). In the past, *in vivo*
158 tissue/blood concentration-time data were a prerequisite for calibrating and evaluating the predictive capability
159 of a PBK model (Bessemers, et al., 2014). The common practice was to start with an animal PBK model, calibrating
160 it with animal *in vivo* data, and then re-parameterizing it based on *in vitro* biotransformation measurements or
161 allometric scaling to develop a human PBK model. As the field of risk assessment evolves towards the goal of
162 reducing, and eventually replacing, the use of animals for predicting human toxicity, PBK model development
163 has seen a shift towards increased use of non-animal data for parameterization, along with increased use of the
164 models for IVIVE. Efforts in this area should be directed towards developing standards that will increase the
165 acceptance of *in vitro* methods for characterizing human-relevant ADME properties. To enhance the acceptance
166 of PBK models at an international level, good modelling practice is required to guide the use of the *in vitro* and
167 *in silico* methodologies in developing PBK models. As the first step, to initiate a dialogue on such a topic, the
168 European Commission’s Joint Research Centre (JRC), EURL ECVAM, hosted a workshop on “Physiologically-Based
169 Kinetic modelling in risk assessment – reaching a whole new level in regulatory decision-making” (Ispra, Italy,
170 November 16–17, 2016). The workshop participants discussed challenges in: 1) applying NG-PBK modelling to

¹ <https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/eurl-ecvam-strategy-achieving-3rs-impact-assessment-toxicokinetics-and-systemic-toxicity?search>

171 support regulatory decision making; 2) constructing PBK models for safety assessment without animal *in vivo*
172 data, relying solely on *in vitro* or *in silico* methods; and 3) assessing the validity of PBK models that rely only upon
173 non-animal data. A portion of this current article summarizes the outcome of the workshop; detailed
174 information on the workshop outcomes can be found in the workshop report (Paini et al., 2017a).

175 In addition to the EURL ECVAM workshop, an international survey was conducted in 2017 to understand the
176 applications of PBK modelling in the broader scientific and regulatory communities. An aggregate summary,
177 including analysis of the results, has been published (Paini et al., 2017b), while results presented per individual
178 country are available online at <http://apps.klimeto.com/pbk/>. The survey provides insight into the current state
179 of knowledge throughout the PBK modelling and user community, as well as a cursory volunteer contact list of
180 modellers available for peer reviewing models. The main findings of the survey showed that though continuous
181 expansion of the modelling community has allowed PBK models to gain ground for use in various scientific and
182 regulatory risk assessment applications, this remains a slow process, due to a lack of guidance, data, and
183 expertise, which continue to limit widespread acceptance of those models in such applications (Paini et al.,
184 2017b). Here, we also discuss recently reported activities in the field, (subsequent to the 2016 EURL ECVAM
185 workshop) that demonstrate both ongoing developments in the field and the continued hesitancy within public
186 health agencies to apply PBK modelling in their decisions. In addition, we will introduce as a new challenge the
187 integration of NG-PBK modelling with toxicodynamic endpoints, as this will be essential for implementation of
188 NG-PBK models.

189

190 **Salient Features: Applying NG-PBK modelling to support regulatory decision making**

191 As concluded from the 2017 survey (Paini 2017b), training, guidance, and dialogue are three main factors that
192 will facilitate the successful acceptance of NG-PBK modelling in regulatory decision-making.

193 **1. Dialogue and Communication**

194 While training and guidance are both essential, their maximum benefits cannot be achieved without frequent
195 dialogue between regulators, modellers, and model proponents (chemical registrants). Such frequent dialogue
196 not only allows the proposers to better understand the needs of the regulators, but also allows the regulators
197 to provide modellers with feedback throughout the development, evaluation, and application processes. For
198 example, risk assessors present at the 2016 EURL ECVAM workshop indicated that they prefer to use the simplest
199 model possible, as finding sufficient input data is rather challenging, but would be willing to use more complex
200 models if necessity dictates and sufficient input data are available. Thus, dialogue can help regulators to convey
201 their needs for specific training and for model features, and help proponents to understand the criteria
202 necessary for regulatory acceptance. Conversely, the regulators can learn what is technically or scientifically
203 feasible and what is not. As such dialogue may prove to be time-consuming, establishing a harmonized template
204 for model construction and evaluation would facilitate the process. The template should be flexible enough for
205 any regulatory agency or country to use, and would ideally incorporate an agreed-upon ontology. To efficiently

206 develop a PBK model to support regulatory risk assessment, modellers and end users (proponents and
207 regulators) need to clearly define their goals of model use and related model requirements at an early stage. For
208 example, if a read-across approach is likely to be applied by the end users, biokinetic data for a pre-determined
209 set of relevant chemicals (target and source chemicals) will constitute important supporting material and should
210 be included in the submission package. In situations where safety assessment is conducted for a new chemical
211 on the market, the following criteria may be used to facilitate regulatory acceptance of a PBK model for this
212 substance: 1) the model should be transparent, with a usable code; 2) model uncertainty should consider
213 biological plausibility, and be clearly described and quantified when possible; 3) uncertainty in exposure
214 scenarios should be characterised, because this uncertainty will propagate to PBK model results; 4) user-friendly
215 platforms should be used where possible; 5) the model should be fit-for-purpose with no unnecessary additional
216 complexity, and with all required parameters measurable; and 6) the model should consider sufficient coverage
217 of chemical space, to allow for read-across approaches if desired. In cases where the model performance needs
218 to be evaluated using human *in vivo* data, regulators may consider using data that are generated from human
219 trials, such as micro-dosing. It should be emphasized that clinical studies would only be conducted once the
220 safety of the chemical has been established and the clinical investigation represents de minimis risk to the
221 subjects.

222

223 **2. Training**

224 Within the current climate of desire to reduce, refine, and replace animal testing through ongoing scientific and
225 technological advancements, it would be beneficial to risk assessors / managers and other workers in safety
226 assessment to be kept abreast of the development of NG-PBK models . In order to achieve this goal, information
227 on a number of novel emerging technologies, in addition to PBK modelling, should be made more accessible.
228 These include -omics, organ- on-a -chip, high-throughput screening methods, read-across, Adverse Outcome
229 Pathways (AOPs), and IVIVE. Additionally, it would be helpful if guidance were available indicating how these
230 different approaches are integrated in support of chemical safety assessment. On the other hand, it is not
231 necessary for risk assessors/managers, etc. to have detailed knowledge related to all the diverse aspects of PBK
232 modelling; rather, it may be sufficient to provide tailored training that focuses only on the specific needs of each
233 regulatory sector and, where applicable, cross-sector needs. For example, some risk assessors may need or wish
234 to run a model, and so they would require knowledge of the relevant software and expertise to review and run
235 model codes. Other risk assessors may rely on a model peer review system to check the implementation and
236 reliability of new model codes, and in this case, may only require sufficient knowledge to allow for interpretation
237 of the data and to enable modelling predictions to be put in context. One option is for risk assessors to assemble
238 technical committees that consist of members possessing a range of expertise, to review the model code and
239 interpret model results. The training content/format should also be tailored to achieve maximum effectiveness
240 in understanding the application of models. In addition to the traditional classroom setting, training formats
241 could include webinars, *ad hoc* short courses, and more refined or specialised graduate-level courses. Further,
242 online training could potentially generate a larger audience that would also allow the modelling and user

243 community to continue to expand. Finally, since risk assessors generally place higher confidence in *in vivo* data,
244 there is a need to make courses on alternative *in vitro* and *in silico* methods more accessible, to provide a path
245 forward to acceptance of these NG-PBK model applications in regulatory decision making.

246 3. Guidance

247 While training is essential, establishing guidance and GMP on PBK model applications intended for regulatory
248 purposes is also critical (Loizou et al., 2008). The GMP should include clear documentation on how to report a
249 model's scope and purposes, details of model development and evaluation, interpretation of results, and
250 applications of the model in risk assessment (Loizou et al., 2008). It is recommended that the individual(s) or
251 community network(s) responsible for each specific step in the development, evaluation, and application
252 process be clearly identified, to increase transparency and allow end users to identify where targeted training
253 may be required, if necessary, for a specific topic. The context in which the model is to be used, and thus the
254 scope of the model development or amendment(s), should be clearly documented. This is especially important
255 to avoid misuse of a reliable model, such as when results of the simulations are applied for the wrong purpose
256 or when the model is applied outside of its applicability domain.

257 The WHO-IPCS published, in 2010, a guidance document on the characterisation and application of PBK models
258 in risk assessment (WHO, 2010). Nevertheless, no comprehensive guidance documentation is currently available
259 for reporting and evaluating NG-PBK models without use of animal *in vivo* TK data, or for interpreting and
260 applying outputs from these models for human safety assessment. Recently, several efforts have been made to
261 produce such documentation. For example, the Scientific Committee for Consumer Safety (SCCS) considers all
262 available scientific data in their safety evaluation of cosmetic substances, including data generated from PBK
263 modelling. In the most recent Notes of Guidance for the Testing of Cosmetic Ingredients and Their Safety
264 Evaluation (SCCS/1564/15)², the SCCS defines the conditions for the use of PBK models submitted for risk
265 assessment purposes. PBK modelling has already been accepted as a tool for risk assessment or for use as
266 supporting information in some of the chemical-specific dossiers evaluated by the SCCS, EFSA, and US-EPA. The
267 SCCS document could act as a starting point or as a template for a new general guidance document. Additionally,
268 the new reporting guidelines from the US Food and Drug Administration (FDA) and European Medicine Agency
269 (EMA) (US FDA, 2018; EMA, 2016), on harmonization of reporting and on qualification of PBK modelling and
270 simulation, can also apply to NG-PBK models. To extend this concept, a working group at the Organisation for
271 Economic Co-operation and Development (OECD), comprised of more than 45 scientists from different areas of
272 scientific expertise, are drafting a guidance document for characterizing, validating, and reporting uncertainties
273 in NG-PBK model applications.

274

275 **Salient Features: Constructing PBK models for safety assessment without animal *in vivo* data**

² http://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_190.pdf

276 PBK models are built using three sets of parameters: i) physiological and anatomical parameters, with
277 representative reference parameters taken from the species under study (animal or human); ii) biokinetic /
278 ADME properties, which can be gathered using *in vitro* methods or by fitting the model to an *in vivo* data set;
279 and iii) physico-chemical parameters, which are experimentally derived or obtained using *in silico* approaches
280 such as quantitative activity relationship (QSAR) models (Rietjens et al., 2011). For GMP, the PBK model
281 construction should consider the compound exposure situation/dosing strategy to be simulated (problem
282 formulation). The exposure descriptions should include route of administration, timeframe of the simulation
283 (i.e. exposure duration), and exposure frequency. In the cases of complex models that include inter-individual
284 variability among some physiological values, the number of individuals that should be incorporated into the
285 simulation for sufficient statistical power analysis should also be considered.

286 In the case of NG-PBK models, assuming there is no possibility of generating *in vivo* animal data for the model
287 calibration, there are two key pre-requisites to build the model:

- 288 • Availability of *in vitro* and *in silico* alternatives to generate ADME properties (including prediction of
289 metabolism) of sufficient quality
- 290 • Availability and accessibility of modelling platforms.

291

292 **1. Availability of *in vitro* and *in silico* data for ADME properties**

293 Without *in vivo* data, the values of parameters in a PBK model will need to be derived from the results of *in silico*
294 or *in vitro* experiments. Clearly, the accuracy of PBK models will be heavily reliant upon the quality of the model
295 parameters, which often are not only tissue dependent but also chemical dependent.

296 As it is useful to determine the minimum requirements for PBK models (with respect to data-poor and data-rich
297 chemicals), a decision tree indicating requirements for different scenarios is presented here (Figure 3). The most
298 minimalistic model type, one-compartment models, parameterised with only protein binding and clearance
299 data, have been developed and used to support chemical screening and prioritization (Rotroff et al., 2010;
300 Wetmore et al., 2012, 2013, 2014; Tonnelier et al., 2012; Yoon et al., 2014; Wambaugh et al. 2015). Depending
301 on the exposure route, a compartment representing the skin, intestine, or lung may need to be included in a
302 model. If a compound is highly lipophilic, a fat compartment is required, and it may also be necessary for the
303 model to describe uptake into the lymphatic system. Finally, depending on the hazard data available, additional
304 compartments and biological processes may need to be added to the PBK model. Throughout development of
305 the model, as more specific information is obtained on the chemical's properties and mode of action (MoA),
306 confidence is increased in the applicability of the models. A good strategy would be to begin with a generic
307 model structure, then move to more specific models once knowledge is gained that indicates a unique biokinetic
308 behavior of the compound in question. In using a simple model, it is possible that a key kinetic pathway specific
309 to a given target chemical will not be taken into consideration. To address this issue, a database of all known
310 ADME/TK processes, such as cell uptake (capturing the role of transporters), metabolism, and efflux, could be
311 developed to help modellers identify which processes may need to be included for a specific chemical / purpose.

312

313 Membrane transporters influence the ADME processes of various endogenous and exogenous compounds
314 (Klaassen and Aleksunes, 2010; SOLVO, 2017). In recent decades, the pharmaceutical field has placed
315 considerable effort into the study of transporters affecting drug disposition, therapeutic efficacy, and adverse
316 outcomes, but little is known in regards to transporter effects on environmental chemicals (Clerbaux et al.,
317 2018). Transporters can play a significant role in chemical distribution. As such, integration of membrane
318 transporter-based experimental data during parameterization of several types of computational models (e.g.,
319 QSAR, pharmacophore, and PBK models), through use of platforms like SimCyp, PKSim, or GastroPlus, will
320 enable better understanding of chemical/drug disposition (Clerbaux et al., 2018).

321

322 Protein binding in plasma influences the partitioning of endogenous and exogenous compounds from the blood
323 into the tissues. The plasma protein binding property is, among other things, related to lipophilicity, as binding
324 becomes greater with more lipophilic chemicals, thus sequestering such chemicals in blood and limiting the
325 systemic availability and distribution of unbound fraction of the chemical. A common and widely used method
326 for estimating plasma protein binding *in vitro* is the rapid equilibrium method, which involves measurement of
327 chemical transport across a dialysis membrane with a high surface area-to-volume ration within a Teflon-lined
328 plate well (Waters et al., 2008).

329

330 Metabolism is an important feature to consider in a model, especially when a metabolite is assumed or known
331 to be the toxic moiety. Both *in vitro* and *in silico* methods can be informative in providing predictions for
332 metabolism and clearance. Kirchmair et al (2015) reviewed software for predicting a range of features associated
333 with metabolism (e.g. identification of labile moieties, enzyme interactions and metabolite prediction).. The
334 focus of these *in silico* tools is mainly the estimation of the qualitative nature of the metabolites (i.e., which
335 metabolites are formed based on the parent compound's molecular structure) and seldom allows for estimation
336 of rate constants. A common criticism of software for predicting metabolites is the tendency for over-prediction:
337 theoretically possible metabolites are not differentiated from those that occur experimentally. Some software
338 platforms have attempted to address this issue through inclusion of filtering rules. For example, in order to
339 reduce over-prediction within the Meteor Nexus software (Lhasa Ltd, Leeds), Marchant et al (2017) describe a
340 process whereby k-nearest neighbor analysis is combined with expert knowledge of biotransformation to reduce
341 the over-prediction of metabolites. Such *in silico* models do not predict efflux of metabolites.

342

343 *In vitro* data for metabolism may be generated using tissue slices, organ (e.g., liver) homogenates, cell lines,
344 spheroids, or (sub)cellular fractions (such as microsomes, baculosomes, S9, and cytosol1), where metabolism is
345 measured as loss of the parent compound or production of metabolite(s). It should be noted that if metabolism
346 occurs very slowly, it may not be detected in a short-term *in vitro* assay. If a chemical is known to be
347 predominantly excreted unchanged in urine, then metabolism is less relevant to the model. However, if
348 metabolism of a parent compound is thought to be metabolized to undergo biliary excretion or to be excreted
349 via the bile, then a model including such elimination pathways is necessary, first by determining which pathways
350 of elimination are most relevant to the target chemical. *In silico* and *in vitro* models have also been developed

351 for predicting different processes involved in elimination. These include *in silico* models for total clearance
352 (Lombardo et al., 2014) and metabolism (Pirovano et al., 2015) and *in vitro* models for biliary excretion (Ghibellini
353 et al., 2006). However, more work is required to develop models for elimination, and the applicability domain
354 for existing models should be carefully considered before application to a wider range of chemicals. A current
355 limitation is that there are no (OECD) guideline(s) addressing *in vitro* methods to determine kinetic parameters,
356 except for the guideline on Skin Absorption (OECD TG 428). In the absence of standardised methods for
357 generating *in vitro* parameters to calibrate PBK models, it is important that *in vitro* metabolism data or data
358 regarding transporters are produced according to the new OECD good *in vitro* method practice (GIVIMP)³. The
359 GIVIMP document is meant to serve as technical guidance on generating and applying quality data through good
360 scientific and quality practices, to support the regulatory human safety assessment of chemicals using *in vitro*
361 methods.

362
363 Bessems et al. (2014) provides a general overview of the currently available *in vitro* and *in silico* methods for
364 characterizing human ADME and the gaps and challenges faced. Mostrag-Szlichtyng et al (2010) provide an
365 extensive review specifically of *in silico* tools (i.e., QSAR models and software) for prediction of ADME properties
366 that are relevant to PBK model building. More recently, Patel et al (2018) have collated and assessed the quality
367 of over 80 models for 31 absorption-, distribution-, and excretion-related endpoints (Patel et al., 2018).

368
369 Finally, toxicodynamic data derived from *in vitro* toxicity tests are typically based on nominal concentrations of
370 the substances, which may contain significant errors due to the loss of biological, physical, and toxicological
371 chemical processes in such tests. An *in vitro* biokinetic study plays a significant role in translating a nominal
372 concentration used in *in vitro* systems to the actual level of cell exposure producing the effect. Several
373 methodologies can be applied to address such a relationship, such as *in vitro* fate and transport mass balance
374 models recently developed by several research teams (Kramer 2010a, 2010b; Armitage et al., 2014; Fischer et
375 al., 2017; Zaldivar Comenges et al., 2017).

376

377 **2. Availability of modelling platforms**

378 Currently, several open source modelling platforms, such as IndusChemFAte (Cefic LRI, [http://cefic-](http://cefic-lri.org/toolbox/induschemfate/)
379 [lri.org/toolbox/induschemfate/](http://cefic-lri.org/toolbox/induschemfate/)), High-Throughput Toxicokinetics (httk)-r package (Wambaugh et al., 2018,
380 <https://cran.r-project.org/web/packages/httk/index.html>), MEGEN-RVis (Loizou et al, 2011;
381 <https://megen.useconnect.co.uk/>), PLETHEM (<http://www.scitovation.com/plethem.html>), MERLIN-EXPO
382 (Ciffroy et al., 2016b; Suciu et al., 2016; <https://merlin-expo.eu/>), and PK-Sim (www.systems-biology.com), and
383 license-based platforms such as GastroPlus (www.simulations-plus.com) and SimCyp
384 (<https://www.certara.com>), are available to individuals possessing varying degrees of expertise in PBK
385 modeling. These platforms provide different computational tools that allow non-programmers to develop and
386 run model simulations with varying options to gain a better understanding of model behavior, which is essential

³ http://www.oecd.org/env/ehs/testing/OECD_Draft_GIVIMP_in_Human_Safety_Assessment.pdf

387 for interpretation of model output. The PBK models run from these platforms can be parameterised using *in*
388 *vitro* or *in silico* data. However, programmers or users with modeling skills can also use R, MATLAB, and Berkeley
389 Madonna software to develop customised PBK models, and to support the generation of innovative modeling
390 components, which might otherwise not be generated through use of the more-structured commercial
391 platforms.

392
393 A concern for the use of open source modelling platforms, as compared to use of their proprietary counterparts,
394 is the lack of sustainable resources and funding that are needed for further development and maintenance of
395 those platforms. While most of these platforms are initiated by a research grant, upon completion of the project,
396 the developers are often unable to find other funding sources to maintain it. In order for a modelling platform
397 to remain sustainable, it is essential to maintain access to the model's equations, so that these can be easily
398 coded later. Sustainability also depends on the ability of model updates to be communicated to end-users.
399 Establishment of an open source library as a repository for all available model information, including a peer
400 review process, is strongly recommended.

401

402

403 **3. Integrating NG-PBK modelling with toxicodynamic endpoints**

404 There is high value in the use of PBK models to predict internal target tissue doses for risk assessment
405 applications, based on the assumption that a similar tissue response arises from an equivalent target tissue dose,
406 rather than the external dose, across different exposure conditions. In addition, toxicodynamic processes that
407 that are interpreted in a high-throughput context from *in vitro* dose–response data can be integrated with PBK
408 models, to link external exposure concentrations to target tissue doses to adverse endpoints. Such integration
409 allows for support of several risk assessment extrapolations, such as QIVIVE and reverse dosimetry approaches.
410 Examples of PBK/TD models are reported in table 3 of Punt et al., 2011. However, the application of PBK/TD
411 models in risk assessment requires proper evaluation of model purpose, model assumptions and structure,
412 mathematical representation, parameter estimation, computer implementation, and predictive capacity.

413 The topic of model evaluation will be captured in the next chapter.

414

415 **Salient Features: Model evaluation- assessing the validity of PBK models that rely only upon non-animal data**

416 A question that often arises is "*How can we trust a PBK model prediction if there are no in vivo data to evaluate*
417 *the simulation; how can the model gain credibility then?*"

418 The following approaches could be applied and are described in further detail below: 1) read-across; 2) micro-
419 scale systems; 3) pragmatic conservative scenario approach; 4) "credibility matrix"; 5) the reliability of dose
420 metric predictions provided with uncertainty and sensitivity analyses (WHO 2010); and 6) population
421 characteristics and virtual population libraries.

422

423 **1. Read-across**

424 For those cases in which *in vivo* data exist for one chemical, a read-across approach⁴ may be applied to
425 parameterize models for other chemicals (Schultz et al., 2015). For example, if a valid PBK model exists for
426 chemical A (source chemical), and chemical B (target chemical) lacks any *in vivo* data and has been shown to be
427 similar in structure to chemical A, then the same parameterised PBK model structure/code and *in vivo* data for
428 chemical A can be used for chemical B. This read-across approach has been demonstrated by case studies
429 applying the PBK Knowledgebase developed by Lu et al. (2016). Alternatively, if parameterisation of the PBK
430 model using available *in vitro* or *in silico* data for chemical B is possible, predictions can be compared to output
431 from the model for chemical A based on *in vivo* data, in order to evaluate the PBK model for chemical B. When
432 using such a model based on similarity between different chemicals, the influence of chemical-specific
433 properties mediating ADME behaviour (e.g., log P, specific functional groups) should be carefully considered.

434

435 **2. Micro-scale systems**

436 Microscale systems, such as human-on-a-chip technology, could potentially be applied to measure and predict
437 kinetics and whole body response to substances (Sung et al., 2014), thus aiding in evaluation and increased
438 confidence in NG-PBK models. However, the limitations of these novel microscale systems should be carefully
439 considered. For example, flow rates from model systems are often not scaled down in a similar manner as tissue
440 volumes, thus rendering interpretation of the data difficult for PBK model applications.

441

442 **3. Pragmatic conservative scenario approach**

443 When *in vivo* data are lacking for model evaluation, a pragmatic conservative scenario could be followed in order
444 to derive the most conservative estimate for risk assessment. For NG-PBK modeling, such an approach needs to
445 be designed in such a way that the structure and input of the model is likely to lead to an overestimation of the
446 internal concentration. This can be achieved by including uncertainty factors in the input parameters of the
447 model. A worst-case estimate for absorption can for example be set to 100%. Other input parameters, such as
448 metabolic clearance can be set to a value that is a certain extent lower than that measured for *in vitro* rates. To
449 define the conservative boundaries around each input parameter, the uncertainties of each *in vitro* or *in silico*
450 input method need to be identified.

451

452 **4. Credibility matrix**

453 There is a need to develop a framework for supporting the credibility of PBK models in support of risk assessment
454 applications. As a first requirement for credibility, PBK models should be biologically plausible. Often, modellers
455 or mathematicians exclude a number of biologically-relevant processes because these processes are considered
456 to have no bearing on the model results and because models should be kept as simple as possible created

⁴ Quotation: "The underlining philosophy of read-across is that substances which are similar in chemical structure will have similar properties and thereby, have similar toxicokinetics and toxicodynamics. Experimental derived toxicological proprieties from one substance, often referred to as source chemical, can be read across to fill the data gap for a second substance, the target chemical, which has a similar molecular structure but is lacking data" (Schultz et al., 2015).

457 following the required purpose/problem formulation. However, such assumptions must always be discussed and
458 agreed upon with biologists and toxicologists, to prevent the omission of critical biological and toxicological
459 steps or key events. Good documentation of model assumptions is critical for modelers to demonstrate the
460 validity of their models to reviewers and users, and visualization is a key feature when dealing with
461 communication of these models. The recent EFSA uncertainty guidance document provides a reporting table for
462 listing and evaluating model uncertainties (EFSA 2018).

463

464 From the 2016 EURL ECVAM workshop, the following graphical representation and application of the “credibility
465 matrix by Patterson & Whelan” has been proposed. The matrix (Figure 4) allows for locating a specific model
466 type based on the information available, i.e whether a model is principled and testable, as well as knowledge of
467 the biology and the availability of data, which should aid in systematically establishing model credibility via a
468 process of social epistemology (Patterson & Whelan, 2017). If a model falls in the bottom left region (testable
469 and with full knowledge), confidence in the model is likely high. However, if a model falls in the top right region
470 of the matrix (not testable and without any knowledge of the system biology), confidence in the model is likely
471 low due to the uncertainties associated with it. In other words, regulators are unlikely to trust model types found
472 in the top right region of the matrix when making decisions. The question is, to what degree a PBK model would
473 need to be placed towards the bottom left corner to attain sufficient credibility for regulators. In some sense,
474 testable models do not really predict, but provide an estimate to compare against available data in a
475 retrospective fashion.

476

477 The proposed framework should lay out the requirements for validating models with different degrees of
478 knowledge and testability (e.g., quantitative validation), which could aid in quantifying the uncertainty currently
479 existing with animal models, and which can help regulators assess whether models developed through *in vitro*
480 and *in silico* methodologies can be equally reliable, or even more so, compared to current risk assessment
481 approaches. Biological systems, by nature, are complex networks operating under simple rules that can be
482 described by non-linear dynamic processes, and which exhibit non-trivial emergent and self-organizing behavior.
483 As a result, a measured value might represent a particular, and perhaps unknown, state of a system, which
484 makes its use, as a comparator for a predicted value, challenging. To handle such issues, approaches that
485 operate on experience-based validation are required. Ideally, these, approaches would capture the diversity of
486 experiences to establish generic digital twins, which are couplings of validated models with their real-world
487 datasets (see Patterson et al., 2016).

488

489 There is disagreement amongst modellers as to the meaning of the terms model evaluation, verification, and
490 validation; for instance, EMA has shifted to use of the word “qualification”. Regardless of which term is more
491 appropriate, the analytical purpose is to ensure that the model is appropriate for the task at hand, and that its
492 predictions are a reasonable representation of reality. Once confirming that the model is a reasonable
493 representation of reality for the intended purpose, several analyses may be used to “validate” a model, including

494 sensitivity analysis, robustness analysis⁵, assumption justification, model argumentation, structured calibration,
495 predictive performance, proper scoring rules, and relation to reality. To “verify” a model, the model scope should
496 be revisited and the model equations and code reviewed. The following key elements were suggested by the
497 2016 EURL ECVAM workshop participants to achieve model credibility (Paini et al., 2017a):

- 498 ✓ Understand the model;
- 499 ✓ Understand the data underpinning the model;
- 500 ✓ State clearly the assumptions and hypothesis encoded;
- 501 ✓ Consider the gap between the model and reality, based on available observations.

502 This last item can be a description of what is lacking in the model. The outcomes of sensitivity analyses can be
503 used to explain some model deficits. One possible approach, as opposed to the statement in the introduction
504 regarding developing the simplest model, would be to start with a more complex model and then remove
505 parameters to which the predictions are not sensitive. The potential problem with this approach is that when
506 there are many parameters with large uncertainties, they may introduce a great deal of variation into the
507 uncertainty analysis.

508

509 **5. Reliability of dose metric predictions (model testing, uncertainty, and sensitivity)**

510 In 2010, the World Health Organization (WHO) reported the level of confidence needed to gain credibility in a
511 PBK model intended for risk assessment (WHO, 2010). The degree of confidence in a PBK model’s predictions
512 depends upon how well the model has been tested against real data and whether adequate sensitivity and
513 uncertainty analyses have been conducted, in order to support the reliability of predictions (WHO, 2010). In the
514 case of NG-PBK models, the lack of “real data” (e.g. *in vivo* human data) that are required to evaluate model
515 predictions for the purpose of validation render such validation nearly impossible. However, reporting of
516 adequate sensitivity and uncertainty is certainly relevant and encouraged. Tables providing guidance in
517 reporting results of uncertainty and sensitivity analyses have been provided in the WHO 2010 article, as a tool
518 to better document the evaluation of model predictions (from WHO 2010; Meek et al. 2013). There are several
519 areas that are considered to present current challenges in accepting model-informed drug development, which
520 can also provide insight into necessary acceptance criteria for PBK model-based drug development. Among
521 those criteria, most noteworthy is that the adequacy of submitted PBK models is to be based on their intended
522 purposes at different stages of drug development (Paini et al., 2017a). That is, determination of whether a model
523 is fit-for-purpose and the need to identify and transparently communicate the knowledge gaps. EMA and US
524 FDA published a draft document in 2016 as guidance on the qualification and reporting of physiologically based
525 pharmacokinetic (PBPK) modelling and simulations (EMA, 2016; US FDA 2018). The aim of this guideline is to
526 describe the expected content that should be included in PBK modelling and simulation reports during regulatory
527 submission, including applications for authorization of medicinal products, pediatric investigation plans, and

⁵ Quotation from Saltelli et al 2000 Sensitivity Analysis – What is Sensitivity Analysis? “For a software engineer, SA could be related to the robustness and reliability of the software with respect to different assumptions “ ... “For a statistician, involved in statistical modelling, SA is mostly known and practice under the heading of “robustness analysis” (Saltelli, 2000).

528 clinical trial applications. This also includes the documentation needed to support the qualification of a PBK
529 platform for an intended use, such as results of sensitivity and uncertainty analyses.

530 **6. Population characteristics and virtual population libraries**

531 This chapter reports information on population characteristics as virtual population libraries for the *in silico*
532 medicine field. However we believe that this information could be also relevant for the chemical risk assessment.
533 Efforts undertaken to better capture the heterogeneity in the human species can certainly be applied to
534 environmental chemical risks, as different population cohorts may be more at risk to specific chemical exposures
535 than are other cohorts. Important aspects of human heterogeneity include inter-individual variations in lifestyle,
536 health status (immunosuppressed, disease patient) genetic polymorphism (gene expression), physiology (uptake
537 rate), biochemistry and molecular biology (McLanahan et al., 2012), all with respect to age. These factors will
538 interact and influence the chemical ADME and biokinetic behaviors and toxicodynamics within the body.
539 Parameters in a PBK model have a direct biological correspondence, providing a useful framework for
540 determining the impact of observed variations in physiological and biochemical factors on the population
541 variability in the achieved target of a particular chemical (Clewell and Andersen, 1996; Price et al., 2003;
542 McLanahan et al., 2012). In addition, integration of genetic information from –omics studies will enhance
543 predictions for precise and personalized medicine. Applications for predicting the kinetics of substances within
544 specific populations, such as in the field of pediatrics, have been increasing in their development and use (Leong
545 et al., 2012). In the pharmaceutical field, population-specific PBK models can simulate untestable clinical
546 outcomes, allowing for evaluating the effects of intrinsic (e.g., organ dysfunction, age, genetics, etc.) and
547 extrinsic (e.g., drug-drug interactions) factors, alone or in combination, on drug target concentrations.

548

549 **Next steps and future perspectives**

550 With an increasing demand for application of alternative methods within the risk assessment framework, the
551 need for the development of higher throughput NG-PBK models has also increased. A guidance document for
552 GMP for PBK modelling could also be extended to other types of *in silico* biokinetic models, such as *in vitro* mass
553 balance models (Armitage et al., 2014; Zaldivar Comenges et al., 2017). Existing guidance documents (WHO,
554 2010 and EPA, 2006), and those documents of EFSA (2014), and European Committee for Standardization (CEN,
555 2015), that are less PBK-specific, require updating with respect to the current trends, due to the continuous
556 evolution in science and risk assessment. The recent United States Food and Drug Administration (US FDA, 2018)
557 and European Medicine Agency (EMA, 2016) guidelines are the first that open up the possibility to submit non-
558 animal PBK model results for drug dossier submission and provide excellent examples that other agencies could
559 follow. At the same time, the OECD is working on a guidance document for the characterization, validation, and
560 reporting of physiologically based models for regulatory applications that should be ready in 2019, and which
561 attempts to set principles for NG-PBK model validation.

562 However, the challenge remains in making appropriate use of *in vitro* data and/or *in silico* predictions when 1)
563 building these models; 2) interpreting model outputs and integrating the outputs with other sources of
564 information for risk assessment purposes; and 3) attempting to gain model credibility by underlining all
565 uncertainties and assumptions when *in vivo* human data are unavailable for proper model evaluation. The
566 uncertainty and variability associated with PBK models, and the proposed GMP (Loizou et al., 2008), should be
567 further developed and should include guidance for PBK models built using *in vitro* and *in silico* methodologies to
568 estimate ADME properties. The use of a matrix in the new risk assessment paradigm, to underline and quantify
569 the uncertainty associated with NG-PBK models, compared to models based on *in vivo* animal data, would be
570 desirable.

571 Several standardised decision trees could be developed to guide modellers in their construction of a PBK model
572 in the absence of *in vivo* data for calibration, and to guide risk assessors in application and interpretation of PBK
573 models. For instance, PBK-predicted internal dose metrics vs. *in vitro* PoD from toxicity testing could be taken
574 into account, along with *in vitro* results linking to *in vivo* adverse outcomes for a tiered assessment, perhaps
575 through application of the traditional and internal threshold of toxicological concern (TTC) approach (Kroes et
576 al., 2007; Worth et al., 2012). With the need for several international working groups to further develop such
577 documentation, communication is required among these groups to ensure compatibility of *in vitro* kinetic and
578 dynamic methods with PBK models, in addition to communication with regulators to fit the total risk-assessment
579 framework. It should be noted that for such communication to be achieved, funding would be necessary.

580 There remains a need to create a community to address issues with human ADME/TK and NG-PBK models, such
581 as the development of criteria for model construction and model evaluation. A group of scientists across the
582 academic, industrial, and governmental landscapes should be available and willing to establish a peer review
583 system for PBK models. Criteria should exist to select those individuals that will review the models, and
584 templates and check lists should be provided to assist in the review process. A public repository is needed for

585 PBK models that have been built and/or peer reviewed, and once this repository is developed, relevant
586 documentation can be introduced from an independent peer review to support model credibility. Such a
587 repository is in line with the work reported in Lu et al., (2016) and will allow for the curation of more case studies
588 and the creation of libraries of *ad hoc* PBK models that could be used for training purposes. Additionally, this
589 repository will facilitate risk assessment approaches applying PBK models and IVIVE, and communicate to
590 decision makers more efficiently the current state of science regarding the use of animal-free models in
591 regulatory applications. Perspectives from the various industrial stakeholders (e.g. pharmaceutical, food safety,
592 agricultural, and personal care product industries) also need to be communicated, to provide greater insight of
593 current practice and understanding of future needs of these sectors, to enable promotion of best practices.

594 Application of NG-PBK models, in the context of exposure in specific population of patients, would be extremely
595 valuable in the generation of virtual population/patient libraries. These libraries would enable clinical trials to
596 entail populations with a greater number of “virtual” individuals, which might not otherwise be possible to
597 conduct with a limited number of real persons/patients. Additionally, these libraries would introduce
598 populations more rarely encountered, such as those possessing enzyme polymorphisms that exert a greater
599 influence on drug-drug interactions or those with rare genetic diseases or health abnormalities. Such libraries
600 would also prove useful in chemical risk assessment when evaluating interindividual variability in relation to
601 chemical exposures and toxicological outcomes.

602 Finally, it is recommended that a means for training new modellers and risk assessors be established . Such
603 training, which can be provided with specific courses or as a continuous education course within scientific
604 conferences, will focus on PBK model development, evaluation, and application. Though several challenges still
605 remain, the suggestions and steps presented in this work provide a path towards gaining acceptance of NG-PBK
606 models in regulatory practices.

607 In summary, to facilitate the development and use of NG-PBK models, which do not rely on animal *in vivo* data,
608 and their acceptance in the regulatory domain, the following are recommended:

609 i) development of more transparent, accessible, and user-friendly software platforms that facilitate
610 development and application of PBK models by a community of users, and which allow specific populations to
611 be modelled or population variability to be evaluated;

612 ii) development of resources to inform new developments in *in silico* and *in vitro* approaches that may be used
613 to provide data for model development;

614 iii) development and refinement of existing web applications and PBK model platforms that have the ability to
615 conduct QIVIVE and reverse dosimetry in an automated manner;

616 iv) knowledge sharing initiatives that allow members of the regulatory community, such as risk assessors and
617 risk managers, to become familiar with relevant PBK model information, while model developers gain a better
618 understanding of regulatory needs;

619 v) GMPs and harmonised guidelines for reporting the steps taken during model development, evaluation, and
620 application, with respect to NG- PBK models. This would include the use of a clear and common terminologies.

621

622

623 **Acknowledgements**

624 The authors would like to provide a special thanks to E. Ahs and G. Tosiou for logistical and practical
625 support during the workshop. The authors thank S. Belz, R. Corvi, P. Prieto-Peraita, A. Richarz, and M.
626 Whelan of the JRC for contributing to discussions during the workshop.

627 **Funding information**

628 This work was supported by the European Union Reference Laboratory for Alternatives to Animal
629 Testing (EURL ECVAM) of the European Commission's Joint Research Centre (JRC), Ispra, Italy. Funding
630 for Dr. Leonard was provided by the Oak Ridge Institute for Science and Education Research
631 Participation Program at the US EPA.

632 **Disclaimer**

633 The views expressed in this paper are those of the authors and do not necessarily reflect the views of their
634 institutions. Authors declare no conflicts of interest.

635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672

References

1. Altenpohl A, Ciffroy P, Paini A, Radovnkovic A, Suci NA, Tanaka T, Tediosi A, Verdonck F (2018). Standard documentation of exposure models: Merlin-Expo case study, Handbook of Environmental Chemistry, Volume 57, Pages 59-76.
2. Andersen & Krishnan (2010). Quantitative Modeling in Toxicology: An Introduction Book Editor(s): Dr. Kannan Krishnan Dr Melvin E. Andersen. Wiley Online Library. First published: 30 March 2010 <https://doi.org/10.1002/9780470686263.ch1>
3. Armitage JM, Wania F, Arnot JA (2014). Application of mass balance models and the chemical activity concept to facilitate the use of in vitro toxicity data for risk assessment. Environ. Sci. Technol., 48 (16), pp. 9770-9779.
4. Barton HA, Bessems J, Bouvier d'Yvoire M, Buist H, Clewell III H, Gundert-Remy U, et al. (2009). Principles of Characterizing and Applying Physiologically-Based Pharmacokinetic and Toxicokinetic Models in Risk Assessment. IPCS project on the Harmonization of Approaches to the Assessment of Risk from Exposure to Chemicals.
5. Barton HA, Chiu WA, Setzer RW, Andersen ME, Bailer AJ, Bois FY, et al. (2007). Characterizing uncertainty and variability in physiologically-based pharmacokinetic (PBPK) models: state of the science and needs for research and implementation. Toxicol Sci, 99(2), 395-402.
6. Bell SM, Chang X, Wambaugh JF, Allen DG, Bartels M, Brouwer KLR, Casey WM, Choksi N, Ferguson SS, Fraczkiwicz G, Jarabek AM, Ke A, Lumen A, Lynn SG, Paini A, Price PS, Ring C, Simon TW, Sipes NS, Sprankle CS, Strickland J, Troutman J, Wetmore BA, Kleinstreuer NC. (2018) In vitro to in vivo extrapolation for high throughput prioritization and decision making. *Toxicol In Vitro*. 2018 Mar;47:213-227.
7. Bessems JG, Loizou G, Krishnan K, Clewell HJ, Bernasconi C, Bois FY, Coecke S, Collnot EM, Diembeck W, Farcal et al. (2014). PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment: recommendations from a joint EPAA--EURL ECVAM ADME workshop. Regul Toxicol Pharmacol. 68(1):119-139.
8. Bischoff KB, Dedrick RL (1968). Thiopental pharmacokinetics. J Pharm Sci. 57(8):1346-1351.
9. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971). Methotrexate pharmacokinetics. J Pharm Sci. 60(8):1128-1133.
10. Blaauboer B, Bayliss MK, Castell J, Evelo CTA, Frazier JM, Groen K, Gulden M, Guillouzo A, Hissink AM, Houston B, Johanson G, de Jongh J, Kedderis GL, Reinhardt CA, van de Sandt JJM, Semino G (1996). The use of biokinetics and in vitro methods in toxicological risk evaluation. The report and recommendations of ECVAM Workshop 15. ATLA 24:473-497.
11. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, Bois FY, Boobis A, Brochot C, Coecke S, Freidig A, Gundert-Remy U, Hartung T, et al. (2007). Physiologically-based Kinetic Modelling (PBK Modelling): meeting the 3Rs agenda. The report and recommendations of ECVAM Workshop 63. ATLA 35(6):661-671.
12. Bois FY, Ochoa JGD, Gajewska M, Kovarich S, Mauch K, Paini A, Péry A, Benito JVS, Teng S, Worth A (2017). Multiscale modelling approaches for assessing cosmetic ingredients safety. Toxicology. 392:130-139.

- 673 13. CEN, European committee for standardization (2015). CEN Workshop on Standard documentation of
674 large chemical exposure models (WS MERLIN-EXPO); CWA 16938 Brussels
675 <https://www.cen.eu/work/areas/chemical/Pages/WS-MerlinExpo.aspx>
- 676 14. Ciffroy P, Altenpohl A, Fait G, Fransman W, Paini A, Radovnikovic A, Simon-Cornu M, Suciú N,
677 Verdonck F (2016a). Development of a standard documentation protocol for communicating exposure
678 models. *Sci Total Environ* 568, 557-565
- 679 15. Ciffroy P, Alfonso B, A. Altenpohl, Z. Banjac, J. Bierkens, C. Brochot, A. Critto, T. De Wilde, G. Fait, A.
680 Tediosi, T. Fierens, J. Garratt, E. Giubilato, E. Grange, E. Johansson, A. Radomyski, K. Reschwann, N.
681 Suciú, M. Van Holderbeke, F. Verdonck, A. Vlajic (2016b). Modelling the exposure to chemicals for risk
682 assessment: a comprehensive library of multimedia and PBPK models for integration, prediction,
683 uncertainty and sensitivity analysis — the MERLIN-expo tool. *Sci. Total Environ.* 568:770-784.
- 684 16. Clerbaux LA, Coecke S, Lumen A, Kliment T, Worth AP, Paini A. (2018) Capturing the applicability
685 of in vitro-in silico membrane transporter data in chemical risk assessment and biomedical research.
686 *Sci Total Environ.* 2018 Dec 15;645:97-108. doi: 10.1016/j.scitotenv.2018.07.122. Epub 2018 Jul 14.
- 687 17. Clewell, H. J., III, and Andersen, M. E. (1996). Use of physiologically based pharmacokinetic
688 modeling to investigate individual versus population risk. *Toxicology* 111, 315–329.
- 689 18. Clewell III HJ, Andersen ME, Blaauboer BJ. (2008) On the incorporation of chemical-specific information
690 in risk assessment. *Toxicology Letters* 180 (2008) 100–109
- 691 19. EFSA. (2014). Scientific opinion on good modelling practice in the context of mechanistic effect models
692 for risk assessment of plant protection products. *EFSA journal*, 12(3): 3589
- 693 20. EFSA (2018). Guidance on Uncertainty in EFSA Scientific Assessment,
694 <http://www.efsa.europa.eu/en/efsajournal/pub/5123>
- 695 21. EMA European Medicine Agency (2016). Draft “Guideline on the qualification and reporting of
696 physiologically based pharmacokinetic (PBPK) modelling and simulation.”
697 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/WC500211
698 315.pdf.
- 699 22. Fischer FC, Henneberger L., König M., Bittermann K., Linden L., Goss K.U., Escher B.I. (2017) Modeling
700 Exposure in the Tox21 in vitro bioassays *Chem. Res. Toxicol.*, 5, pp. 1197-1208.
- 701 23. Ghibellini G, Leslie EM, & Brouwer KLR (2006). Methods to Evaluate Biliary Excretion of Drugs in
702 Humans: an Updated Review. *Mol Pharm.* 3(3): 198–211.
- 703 24. Groothuis FA, Heringa MB, Nicol B, Hermens JL, Blaauboer BJ, and Kramer NI (2015). Dose metric
704 considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations. *Toxicology*,
705 332, 30-40.
- 706 25. Kirchmair J, Göller AH, Lang D, Kunze J, Testa B, Wilson ID et al. (2015). Predicting drug metabolism:
707 experiment and/or computation? (2015). *Nature Reviews Drug Discovery*, 14(6), 387-404.
- 708 26. Klaassen, CD., Aleksunes LM., (2010) Xenobiotic, bile acid, and cholesterol transporters. *Pharmacol.*
709 *Rev.*, 62 (1) , pp. 1-96.

710

- 711 27. Kramer NI, Busser FJ, Oosterwijk MT, Schirmer K, Escher BI, Hermens, JL (2010a). Development of a
712 partition-controlled dosing system for cell assays. *Chemical research in toxicology*, 23(11), 1806-1814.
- 713 28. Kramer NI (2010b). Measuring, modeling, and increasing the free concentration of test chemicals in cell
714 assays. Utrecht University.
- 715 29. Krishnan & Peyret (2009). Physiologically Based Toxicokinetic (PBTK) Modeling in *Ecotoxicology J.*
716 Devillers (ed.), *Ecotoxicology Modeling, Emerging Topics in Ecotoxicology: Principles, Approaches and*
717 *Perspectives 2*, DOI 10.1007/978-1-4419-0197-2 6, Springer Science+Business Media, LLC 2009
- 718 30. Kroes R, Renwick AG, Feron V, Galli CL, Gibney M, Greim H, Guy RH, Lhuguenot JC, van de Sandt JJM
719 (2007). Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic
720 ingredients. *Food Chem. Toxicol.* 45: 2533-2562
- 721 31. Laroche C, Aggarwal M, Bender H, Benndorf P, Birk B, Crozier J, Dal Negro G, De Gaetano F, Desaintes
722 C, Gardner I, Hubesch B, Irizar A, John D, Kumar V, Lostia A, Manou I, Monshouwer M, Müller BP, Paini
723 A, Reid K, Rowan T, Sachana M, Schutte K, Stirling C, Taalman R, van Aerts L, Weissenhorn R8, Sauer
724 UG25. (2018) Finding Synergies for 3Rs – Toxicokinetics and Read-Across: Report from an EPAA
725 Partners' Forum *Regul Toxicol Pharmacol.* 2018 Aug 23;99:5-21
- 726 32. Leong, R., Vieira, M. L. T., Zhao, P., Mulugeta, Y., Lee, C. S., Huang, S.-M. and Burckart, G. J. (2012).
727 Regulatory Experience With Physiologically Based Pharmacokinetic Modeling for Pediatric Drug Trials.
728 *Clinical Pharmacology & Therapeutics*, 91(5): 926–931. doi:10.1038/clpt.2012.19
- 729 33. Loizou GD, Spendiff M, Barton HA, Bessems J, Bois FY, Bouvier M et al. (2008). Development of Good
730 Modelling Practice for Physiologically Based Pharmacokinetic Models for Use in Risk Assessment: The
731 First Steps. *Reg. Toxicol. Pharmacol.*, 50(3), 400-411.
- 732 34. Loizou GD & Hogg A (2011). MEGen: A Physiologically Based Pharmacokinetic Model Generator.
733 *Frontiers in Pharmacology*, 2 (56), 1-14, 10.3389/fphar.2011.00056.
- 734 35. Lousse J, Bosgra S, Blaauboer BJ, Rietjens IM, Verwei M (2015). Prediction of in vivo developmental
735 toxicity of all-trans-retinoic acid based on in vitro toxicity data and in silico physiologically based kinetic
736 modeling. *Arch Toxicol.* 89(7):1135-1148.
- 737 36. Lousse J, Beekmann K, Rietjens IM (2017) Use of Physiologically Based Kinetic Modeling-Based Reverse
738 Dosimetry to Predict in Vivo Toxicity from in Vitro Data. *Chem Res Toxicol.* 17; 30(1):114-125.
- 739 37. Lowenthal DT, Briggs WA, Levy G (1974). Kinetics of salicylate elimination by anephric patients. *J Clin*
740 *Invest.* 54(5):1221-1226.
- 741 38. Lu J, Goldsmith MR, Grulke CM, Chang DT, Brooks RD, Leonard JA, & Johnson J.(2016). Developing a
742 physiologically-based pharmacokinetic model knowledgebase in support of provisional model
743 construction. *PLoS Comput. Biol.*, 12 (2).
- 744 39. Marchant CA, Rosser, EM, Vessey JD (2017). A k-Nearest Neighbours Approach Using Metabolism-
745 related Fingerprints to Improve In Silico Metabolite Ranking. *Molecular informatics*, 36(3).
- 746 40. McLanahan et al. (2012). Physiologically based pharmacokinetic model use in risk assessment-
747 -Why being published is not enough. *Tox. Sci.*, 126: 5-15.

- 748 41. Meek, ME., Barton, HA, Bessems, JG, Lipscomb, JC, Krishnan K, (2013) Case study illustrating the WHO
749 IPCS guidance on characterization and application of physiologically based pharmacokinetic models in
750 risk assessment, *Regulatory Toxicology and Pharmacology*, 66 (1), 116-129.
- 751 42. Mostrag-Szlichtyng A, Worth A (2010). In silico modelling of microbial and human metabolism: a case
752 study with the fungicide carbendazim. JRC Technical Report EUR 24377 EN.
- 753 43. Mumtaz M, Fisher J, Blount B, Ruiz P (2012). Application of Physiologically Based Pharmacokinetic
754 Models in Chemical Risk Assessment. *Journal of Toxicology* Volume 2012, Article ID 904603, 11 pages.
- 755 44. Paini A, Joossens E, Bessems J, Desalegn A, Dorne JL, Gosling JP, Heringa M, Klaric M, Kramer N, Loizou
756 G, Lousse J, Lumen A, Madden J, Patterson E, Duarte Proenca S, Punt A, Setzer WS, Suci N, Troutman
757 J, Tan YM (2017a). EURL ECVAM Workshop On New Generation of Physiologically-Based Kinetic Models
758 In Risk Assessment. 10.2760/619902.
- 759 45. Paini A, Leonard JA, Kliment T, Tan YM, Worth A (2017b). Investigating the state of physiologically based
760 kinetic modelling practices and challenges associated with gaining regulatory acceptance of model
761 applications. *Regulatory Toxicology and Pharmacology* 90, 104-115.
- 762 46. Patel M, Chilton ML, Sartini A, Gibson L, Barber C, Covy-Crump L, Przybylak KR, Cronin MTD, Madden JC
763 (2018). Assessment and reproducibility of quantitative structure-activity relationship models by the
764 non-expert, *Journal of Chemical Information and Modelling* 58(3):673-682.
- 765 47. Patterson EA, Taylor RJ, Bankhead M. (2016). A framework for an integrated nuclear digital
766 environment, *Progress in Nuclear Energy* 87:97-103.
- 767 48. Patterson EA, & Whelan MP. (2017). A framework to establish credibility of computational models in
768 biology, *Progress in Biophysics & Molecular Biology*, 129:13-19.
- 769 49. Pirovano A, Brandmaier S, Huijbregts MAJ, Ragas AMJ, Veltman K, & Hendriks AJ. (2015). The utilisation
770 of structural descriptors to predict metabolic constants of xenobiotics in mammals. *Environmental*
771 *Toxicology and Pharmacology* 39(1), 247–258.
- 772 50. Price, P. S., Conolly, R. B., Chaisson, C. F., Gross, E. A., Young, J. S., Mathis, E. T., and Tedder,
773 D. R. (2003). Modeling interindividual variation in physiological factors used in PBPK models
774 of humans. *Crit. Rev. Toxicol.* 33, 469–503.
- 775 51. Punt A, Bouwmeester H, Peijnenburg AACM (2017). Non-animal approaches for kinetics in risk
776 evaluations of food chemicals ALTEX 34 , 501-514.
- 777 52. Punt A, Bouwmeester H, Schiffelers MJWA, Peijnenburg AACM (2018). Expert opinions on the
778 acceptance of alternative methods in food safety evaluations: Formulating recommendations to
779 increase acceptance of non-animal methods for kinetics. *Regulatory Toxicology and Pharmacology*, 92,
780 145-151
- 781 53. Rietjens IMCM, Lousse J, Punt A (2011). Tutorial on physiologically based kinetic modeling in molecular
782 nutrition and food research. *Mol Nutr Food Res* 55:941–956
- 783 54. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson
784 RS, Smith CM, et al. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro
785 toxicity screening. *Toxicol. Sci.* 117, 348–358.

- 786 55. Saltelli A. What is Sensitivity Analysis? (2000). in Sensitivity Analysis Edited by Saltelli et al., John Wiley
787 & Sons Ltd. Pp. 3-13.
- 788 56. SOLVO (2017) Biotechnology, SOLVO The Transporter Book (3rd Edition), Produced and Published by
789 SOLVO Biotechnology(2017)
- 790 57. Suciu N, Tediosi A, Ciffroy P, Altenpohl A, Brochot C, Verdonck F, et al. (2016). Potential for MERLIN-
791 Expo, an advanced tool for higher tier exposure assessment, within the EU chemical legislative
792 frameworks. *Sci Total Environ*, 562, 474-479.
- 793 58. Sung JH, Srinivasan B, Esch MB, McLamb WT, Bernabini C, Shuler ML, Hickman JJ (2014). Using
794 physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian
795 response to drug and chemical exposure. *Exp Biol Med (Maywood)*. 239(9):1225-1239.
- 796 59. US EPA (U.S. Environmental Protection Agency) (2006). Approaches for the Application of
797 Physiologically Based Pharmacokinetic (PBPK) Models and Supporting Data in Risk Assessment (Final
798 Report). National Center for Environmental Assessment, Washington, DC. EPA/600/R- 05/043F.
- 799 60. Teorell T (1937). Kinetics of the distribution of substances administered to the body II. The extravascular
800 mode of administration. *Arch Int Pharm Ther* 57:205–240
- 801 61. Tonnelier A, Coecke S, Zaldívar JM (2012). Screening of chemicals for human bioaccumulative potential
802 with a physiologically based toxicokinetic model. *Arch. Toxicol.* 86, 393–403.
- 803 62. US FDA (U.S. Food and Drug Administration) (2018). Draft "Physiologically Based Pharmacokinetic
804 Analyses — Format and Content Guidance for Industry". [https://www.fda.gov/ucm/groups/fdagov-
805 public/@fdagov-drugs-gen/documents/document/ucm531207.pdf](https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm531207.pdf)
- 806 63. Wagner C, Zhao P, Pan Y, Hsu V, Grillo J, Huang S, Sinha V. (2015). Application of Physiologically Based
807 Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on
808 PBPK. *CPT: Pharmacometrics Syst. Pharmacol.*, 4(4): 226–230.
- 809 64. Wambaugh JF, Wetmore, BA, Pearce R, Strope C, Goldsmith R, Sluka JP, Sedykh A, Tropsha A, Bosgra S,
810 Shah I, Judson R, Thomas RS, Setzer RW (2015). Toxicokinetic triage for environmental chemicals.
811 *Toxicol. Sci.*, 147, 55-67
- 812 65. Waters NJ, Jones R, Williams G, Sohal B. (2008) Validation of a rapid equilibrium dialysis approach for
813 the measurement of plasma protein binding. *J Pharm Sci.* 2008 Oct;97(10):4586-95. doi: 10.1002/jps.21317.
- 814 66. Wetmore BA, Wambaugh JF, Ferguson SS, Sochaski MA, Rotroff DM, Freeman K, Clewell HJ III, Dix DJ,
815 Andersen ME, Houck KA, et al. (2012). Integration of dosimetry, exposure, and high-throughput
816 screening data in chemical toxicity assessment. *Toxicol. Sci.* 125, 157–174.
- 817 67. Wetmore BA, Wambaugh JF, Ferguson SS, Li L, Clewell HJ, Judson RS, Freeman K, Bao W, Sochaski MA,
818 Chu TM, et al. (2013). Relative impact of incorporating pharmacokinetics on predicting in vivo hazard
819 and mode of action from high-throughput in vitro toxicity assays. *Toxicol. Sci.* 132,327–346.
- 820 68. Wetmore BA, Allen B, Clewell HJ, Parker T, Wambaugh JF, Almond LM, Sochaski MA, Thomas RS. (2014).
821 Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput
822 toxicity testing. *Toxicol. Sci.* 142, 210–224.

- 823 69. Wetmore BA (2015). Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment
824 Toxicology 332, 94-101.
- 825 70. WHO/IPCS (World Health Organization. International Programme on Chemical Safety). (2010).
826 Characterization and Application of Physiologically Based Pharmacokinetic Models in Risk Assessment.
827 Harmonization Project Document No. 9. Geneva, Switzerland.
- 828 71. Worth A, Cronin M, Enoch S, Fioravanzo E, Fuart-Gatnik M, Pavan M, Yang C, (2012). Applicability of the
829 Threshold of Toxicological Concern (TTC) approach to cosmetics – preliminary analysis. JRC report EUR
830 25162 EN. Publications Office of the European Union, Luxembourg, 2012, available
831 at: <http://publications.jrc.ec.europa.eu/repository/>
- 832 72. Yoon M, Campbell JL, Andersen ME, Clewell HJ. (2012). Quantitative in vitro to in vivo extrapolation of
833 cell-based toxicity assay results. Critical reviews in toxicology, 42(8), 633-652.
- 834 73. Yoon M, Efremenko A, Blaauboer BJ, Clewell HJ. (2014). Evaluation of simple in vitro to in vivo
835 extrapolation approaches for environmental compounds. Toxicol. in vitro 28, 164–170.
- 836 74. Yoon M, Kedderis GL, Yan GZ, Clewell HJ. 3rd. (2015). Use of in vitro data in developing a physiologically
837 based pharmacokinetic model: Carbaryl as a case study. Toxicology 5;332:52-66.
- 838 75. Zaldivar Comenges JM, Joossens E, Sala Benito JV, Worth A, Paini A (2017). Theoretical and
839 mathematical foundation of the virtual cell based assay – a review. Toxicol. In Vitro Volume 45, Part 2,
840 Pages 209-221

841

842 **Figure Legend**

843 **Figure 1.** (a) Schematic representation of a physiologically based kinetic (PBK) model, (b) with an example of a typical PBK
844 model-output (time-dependent chemical concentration in blood).


845 **Figure 2. A.** Number of papers published per year within the last 60 years. The search was conducted using the online
846 repository PubMed on the 7th of March 2018, with key words string including “PBPK OR PBBK OR PBTK OR PBK”. **B.** The
847 number of papers (figure 2 A) published with key words string including “PBPK OR PBBK OR PBTK OR PBK” were normalized
848 to the following terms: Toxicology; Pharmacology; Chemical Safety OR Risk assessment; Forensic Sciences and Veterinary.

849 **Figure 3.** An example of a schematic decision tree to decide what tier of PBK model to apply when encountering
850 data-poor or data-rich chemicals during model parameterization and based on problem formulation.


851 **Figure 4.** Credibility matrix showing comparative loci for a model based on traditional *in vivo* data-based approaches and for
852 a model based on an alternative approach (i.e., *in vitro*, *in silico* methods and/or micro-scale systems). The rationale for the
853 locations of the model types, indicated by stars and letters, are given in the side-bar legend. For example, *in silico* models
854 placed at the top right, might consist of a simple model ‘a’ based on a limited set of data, for instance in a QSAR. This leads
855 to a more sophisticated, but still heuristic, model ‘b’ based on the understanding gained from model ‘a’. The predictions
856 from models ‘a’ and ‘b’ are used to design *in vitro* tests that enable the development of model ‘c’, which can be validated
857 using the rational-empirical approach, thus enhancing its credibility. Finally, this leads to the development of clinical studies
858 and model ‘d’, supported by its predecessors and quantitatively validated or confirmed using clinical data. This places model
859 ‘d’ in the bottom left corner, as a model whose predictions stakeholders, including regulators, practitioners, and patients,
860 will likely use to make decisions (adapted from Paini et al., 2017a, proposed by Patterson and Whelan 2017).

861

862




863




864

865 Figure 1. Painsi et al.,

866



A.




B.

867

868

869 Figure 2 Paini et al.,

870



MoA = Mode of Action; WF = workflow; PBK = Physiologically based kinetic; KB = Knowledge Base

*For instance predictions of input parameter estimated using QSARs

** For instance R/Httk, Plethem, SimCyp, Gastroplus, Pksim, IndusChemFate among others

***QUALITY OF INPUT DATA

In vitro:

- a. Capture in vitro artefacts
- b. If available follow OECD TG or Guidance Document on Good In Vitro Method Practices (GIVIMP)
- c. Report results applying OECD harmonized templates

In silico (applicable to QSARs):


follow the OECD 5 principles for validation:

- a. a defined endpoint
- b. an unambiguous algorithm
- c. a defined domain of applicability
- d. appropriate measures of goodness-of-fit, robustness and predictivity
- e. a mechanistic interpretation, if possible

Human/animal (bio)monitoring data

871

872 Figure 3. Paini et al



Alternative approach

- (a) *in silico* model based on untested hypothesis with no reference data
- (b) Heuristic model based on understanding gained from (a);
- (c) Predictive model based on understanding from (b) & supported by well-designed (using heuristic model) *in vitro* tests;
- (d) Predictive model based on understanding gained from (c) & supported by human data and will be used for decision-making.

Traditional approach

- (α) Predictive model based on & supported by *in vitro* tests using hypothesis driven experiment design;
- (β) Predictive model based on understanding from (α) & supported by animal data from *in vivo* tests and will be used for decision-making.

NOTE:

Exact position of model in each box depends on the case being considered; as does allocation to a box when model lies on a boundary.

873

874

875 Figure 4. Painsi et al.

876

877